Tuesday, 15 February 2011

BrainStorm's ALS therapy wins orphan drug status from FDA

"BrainStorm's therapies are based on research conducted by neurologist Prof. Eldad Melamed and cell biologist Prof. Daniel Offen. The target diseases are ALS and other degenerative neurological conditions such as Parkinson's, multiple sclerosis and spinal cord injuries."  For more click here.